Patents Issued in June 16, 2016
-
Publication number: 20160168237Abstract: The present disclosure relates to, inter alia, a method of treating a complement mediated disorder caused by an infectious agents in a patient, comprising administering an effective amount of a C5 inhibitor, such as eculizumab or an eculizumab variant, to the patient.Type: ApplicationFiled: December 11, 2015Publication date: June 16, 2016Inventors: Darrell Fontenot, Bridget Puffer, Bruce Andrien, Mittie Doyle, Paul Tamburini, Camille Bedrosian
-
Publication number: 20160168238Abstract: The present invention encompasses humanized antibodies that specifically bind N2 peptide, methods for the preparation thereof and methods for the use thereof.Type: ApplicationFiled: December 14, 2015Publication date: June 16, 2016Inventor: Robyn J. Puro
-
Publication number: 20160168239Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.Type: ApplicationFiled: February 19, 2016Publication date: June 16, 2016Inventor: David R. Elmaleh
-
Publication number: 20160168240Abstract: The present invention relates to the use of a VEGF antagonist in the treatment of chorioretinal neovascular or permeability disorders in children. In particular, the invention provides a VEGF antagonist for use in a method for treating a child having CNV or ME, wherein said method comprises administering to the eye of a child a VEGF antagonist that either does not enter or is rapidly cleared from the systemic circulation. The VEGF antagonist may be administered intravitreally, e.g. through injection, or topically, e.g. in form of eye drops. The invention further provides the use of a VEGF antagonist in the manufacture of a medicament for treating a child having a chorioretinal neovascular or permeability disorder.Type: ApplicationFiled: July 9, 2014Publication date: June 16, 2016Inventors: Sergey AKSENOV, Gabriela BURIAN
-
Publication number: 20160168241Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.Type: ApplicationFiled: February 15, 2016Publication date: June 16, 2016Inventor: Christopher J. Paszty
-
Publication number: 20160168242Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.Type: ApplicationFiled: November 10, 2015Publication date: June 16, 2016Inventors: Philip E. HASS, Meredith HAZEN, Yi-Chun HSIAO, Rajita KHOSLA, Gerald R. NAKAMURA, Dhaya SESHASAYEE, Menno VAN LOOKEREN CAMPAGNE, Hongkang XI, Wenwu ZHAI, Jack BEVERS, III, Nancy CHIANG
-
Publication number: 20160168243Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.Type: ApplicationFiled: December 14, 2015Publication date: June 16, 2016Inventor: Jeffrey T.L. SMITH
-
Publication number: 20160168244Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.Type: ApplicationFiled: February 16, 2016Publication date: June 16, 2016Inventors: Joerg Zeller, Kristian T. Poulsen, Yasmina Noubia Abdiche, Jaume Pons, Sierra Jones Collier, Arnon Rosenthal
-
Publication number: 20160168245Abstract: The present invention relates to methods for treating ischemic stroke including extension of the therapeutic time window for reperfusion. More particularly, the invention relates to a method of treating stroke in a subject by inhibiting the transient receptor potential melastatin 4 (TRPM4) channel. The present invention also provides uses of TRPM4 inhibitors, TRPM4 antibodies and kits for use in the methods of the invention.Type: ApplicationFiled: June 30, 2014Publication date: June 16, 2016Inventors: Ping Liao, Kok Poh Loh
-
Publication number: 20160168246Abstract: Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer.Type: ApplicationFiled: September 1, 2014Publication date: June 16, 2016Inventor: Jill P. Smith
-
Publication number: 20160168247Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.Type: ApplicationFiled: July 4, 2014Publication date: June 16, 2016Inventors: Edward VAN DEN BRINK, Joost J. NEIJSSEN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Paul PARREN
-
Publication number: 20160168248Abstract: The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates ?CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon ?CD3/?GITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed. In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g.Type: ApplicationFiled: November 13, 2015Publication date: June 16, 2016Inventors: Randolph J. NOELLE, Li Wang
-
Publication number: 20160168249Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.Type: ApplicationFiled: February 19, 2016Publication date: June 16, 2016Applicant: E.R. SQUIBB & SONS, L.L.C.Inventors: Alan J. Korman, Mark J. Selby, Li-Sheng Lu, Alison J. Witte, Haichun Huang
-
Publication number: 20160168250Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.Type: ApplicationFiled: October 19, 2015Publication date: June 16, 2016Inventors: Avi ASHKENAZI, Jing QING, Christian WIESMANN, Yan WU
-
Publication number: 20160168251Abstract: Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.Type: ApplicationFiled: June 19, 2015Publication date: June 16, 2016Inventors: Alisa WATERMAN, Daniel RAJOTTE, Tobias LITZENBURGER, Alexandra KRAUS
-
Publication number: 20160168252Abstract: The present invention relates to antagonists or inhibitors, which bind selectively to RANKL/OPGbp and regulate the interaction between RANKL/OPGbp and RANK/OPG. In particular, the present invention relates to an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a RANKL/OPGbppeptide for use in the treatment, prevention or alleviation of male infertility or reduced male fertility such as oligospermia or azospermia.Type: ApplicationFiled: August 4, 2014Publication date: June 16, 2016Inventor: Martin Blomberg Jensen
-
Publication number: 20160168253Abstract: The invention relates to a fusion protein comprising an antibody directed to A?, a monovalent binding entity which binds to a blood brain barrier receptor and a neprilysin.Type: ApplicationFiled: July 30, 2014Publication date: June 16, 2016Applicant: Hoffmann- La Roche Inc.Inventors: Bernd Bohrmann, Per-Ola Freskgard, Hendrik Knoetgen, Jens Niewoehner
-
Publication number: 20160168254Abstract: The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.Type: ApplicationFiled: February 4, 2016Publication date: June 16, 2016Applicant: CureVac AGInventors: Ingmar HOERR, Jochen PROBST, Steve PASCOLO
-
Publication number: 20160168255Abstract: The present invention relates to the use of BAG3 receptor-binding molecules as a medicament, in particular for use in the treatment of diseases of an immune, inflammatory, cardiovascular, neoplastic and/or degenerative nature.Type: ApplicationFiled: July 23, 2014Publication date: June 16, 2016Inventor: Maria Caterina TURCO
-
Publication number: 20160168256Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: ApplicationFiled: December 15, 2015Publication date: June 16, 2016Inventors: RAMAKRISHNAN MELARKODE, PRADIP NAIR, SUNDARAJ DAVID RAJKUMAR, KEDARNATH NANJUND SASTRY, MONALISA CHATTERJI, LAXMI ADHIKARY, HEMA BALASUBRAMANIAN, JOSE ENRIQUE MONTERO CASIMIRO, JOSEFA LOMBARDERO VALLADARES, ROLANDO PEREZ RODRIGUEZ
-
Publication number: 20160168257Abstract: Disclosed herein are novel CD180 binding molecules, methods for their identification, and methods for their use.Type: ApplicationFiled: January 12, 2016Publication date: June 16, 2016Inventors: Jay Chaplin, Martha Hayden-Ledbetter, Jeffrey Ledbetter, Edward A. Clark
-
Publication number: 20160168258Abstract: The present invention relates to bi-specific adapters for re-directing viruses to non-virus specific host cells, to expression cassettes comprising a DNA molecule having a nucleotide sequence encoding such bi-specific adapters, to recombinant Coronaviruses comprising such expression cassettes and to their use as a medicament and their use in the treatment of tumors.Type: ApplicationFiled: March 12, 2013Publication date: June 16, 2016Inventors: Hélène VERHEIJE, Paul VAN BERGEN EN HENEGOUWEN, Peter ROTTIER, Marta KIJANKA
-
Publication number: 20160168259Abstract: The present inventor discovered stabilizing agents/stabilizing conditions for suppressing isomerization reactions of sc(Fv)2. It was also discovered that the above-mentioned isomerization reactions can be suppressed through use of freeze-dried formulations. As disclosed herein, by applying the discovered stabilizing agents/stabilizing conditions or the freeze-dried formulation, the isomerization reaction of an sc(Fv)2-type molecule from the bivalent scFv type to the single chain diabody type, and/or the isomerization reaction from a single chain diabody type to a bivalent scFv type can be suppressed in both directions or one direction.Type: ApplicationFiled: December 14, 2015Publication date: June 16, 2016Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventor: Tomoyuki Igawa
-
Publication number: 20160168260Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.Type: ApplicationFiled: February 18, 2016Publication date: June 16, 2016Inventors: NAGARAJ GOVINDAPPA, KEDARNATH SASTRY, MARIA MELINA SOARES
-
Publication number: 20160168261Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of detecting or determining the presence of STEAP-1 proteins are provided.Type: ApplicationFiled: November 30, 2015Publication date: June 16, 2016Applicant: Genentech, Inc.Inventors: Mark DENNIS, Jan MARIK, Paul POLAKIS, Bonnee RUBINFELD, Simon WILLIAMS
-
Publication number: 20160168262Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.Type: ApplicationFiled: September 10, 2015Publication date: June 16, 2016Applicant: Memorial Sloan Kettering Cancer CenterInventors: David Spriggs, Dharmarao Thapi
-
Publication number: 20160168263Abstract: We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are promising therapeutic agents.Type: ApplicationFiled: July 9, 2014Publication date: June 16, 2016Applicants: DUKE UNIVERSITY, THE GOVERNMENT OF THE U.S. AS REPRESENTED BY THE SECRETARY OF HEALTHInventors: Darell D. Bigner, John Sampson, Chien-Tsun Kuan, Mingqing Cai, Bryan D. Choi, Patrick C. Gedeon, Ira H. Pastan
-
Publication number: 20160168264Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.Type: ApplicationFiled: December 15, 2015Publication date: June 16, 2016Applicants: U3 PHARMA GMBH, AMGEN, INC.Inventors: MIKE ROTHE, MARTIN TREDER, ERIC BORGES, SUSANNE HARTMANN, LARRY L. GREEN
-
Publication number: 20160168265Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.Type: ApplicationFiled: October 1, 2015Publication date: June 16, 2016Inventors: James D. Marks, Isin N. Geren, Maria Consuelo Garcia, Jianlong Lou, Ali Razai
-
Publication number: 20160168266Abstract: The present application provides the medicaments comprising the antibodies binding to phospholipase D4 (PLD4) as well as a method using said medicaments for detecting and suppressing activated B cells. The present application is further directed to therapy of auto-immune diseases and allergosis, resulting from the active-repressing function. In order to solves these problems, the present application provides that a monoclonal antibody binding to the extracellular domain of phospholipase D4 (PLD4) protein, or a fragment containing an antigen-binding region thereof as an active ingredient.Type: ApplicationFiled: July 30, 2014Publication date: June 16, 2016Applicant: SBI BIOTECH CO., LTD.Inventors: Tomohide Yamazaki, Mayuki Endo, Koji Ishida
-
Publication number: 20160168267Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: February 3, 2016Publication date: June 16, 2016Inventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan Mcafoose, Marcel Maier
-
Publication number: 20160168268Abstract: The present disclosure provides antibodies that specifically bind to circulating and receptor-bound IgE and inhibit IgE-mediated cell activation. The antibodies find use in various treatment, diagnostic, and monitoring applications, which are also provided.Type: ApplicationFiled: July 25, 2014Publication date: June 16, 2016Inventors: Ke Zhang, Andrew Saxon
-
Publication number: 20160168269Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.Type: ApplicationFiled: December 14, 2015Publication date: June 16, 2016Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
-
Publication number: 20160168270Abstract: Methods for preventing or treating pain are provided. Such methods comprise administering to a subject (e.g., a human subject) an antibody or antibody fragment that binds LPA. The antibody may be a humanized monoclonal antibody.Type: ApplicationFiled: February 18, 2016Publication date: June 16, 2016Inventors: Roger A. SABBADINI, Rosalia MATTEO
-
Publication number: 20160168271Abstract: Provided is a method for producing an alkyl cellulose having a high viscosity and not having an excessively high gel strength. More specifically, there is provided a method for producing an alkyl cellulose comprising the steps of: mixing a cellulose pulp with a first alkali metal hydroxide solution with stirring to obtain alkali cellulose; reacting the alkali cellulose with an alkylating agent to obtain a first reaction mixture; blending a second alkali metal hydroxide solution with the first reaction mixture with stirring, without further blending of the alkylating agent, to obtain a second reaction mixture; and purifying the second reaction mixture to obtain an alkyl cellulose. There is also provided an alkyl cellulose being produced by the above method and having a degree of substitution of alkyl group of 27 to 33% by weight.Type: ApplicationFiled: December 10, 2015Publication date: June 16, 2016Inventors: Akira Kitamura, Atsushi Yamamoto, Mitsuo Narita, Heiko Nebel, Andreas Schultz
-
Publication number: 20160168272Abstract: This invention provides a process for producing a nanocellulose-lignin material, comprising: providing a starting material comprising lignin and discrete cellulose fiber fines, chemically and physically separate from the lignin; and mechanically refining the starting material to form a nanocellulose-lignin material comprising cellulose nanofibrils and/or cellulose nanocrystals chemically or physically associated with the lignin. In certain embodiments, the starting material contains about 60 wt % lignin and about 40 wt % cellulose fiber fines on a dry basis. The starting material may be obtained from an AVAP® process. The refining may utilize single disk refiners, double disk refiners, conical refiners, cylindrical refiners, beaters, grinders, homogenizers, microfluidizers, vortex mixers, rotor-stator mixers, and/or high-shear mixers, for example. A novel nanocellulose-lignin composite material is obtained.Type: ApplicationFiled: June 24, 2015Publication date: June 16, 2016Inventors: Theodora RETSINA, Kimberly NELSON
-
Publication number: 20160168273Abstract: The invention relates to plant-derived cellulose-containing particles useful as rheology modifiers and to a process for preparing cellulose-containing particles from plant material, which process involves treating said plant material with a peroxide reagent. The process can be controlled to produce cellulose-containing particle having a viscosity up to about 7500 or 8000 cps.Type: ApplicationFiled: March 18, 2014Publication date: June 16, 2016Inventors: David HEPWORTH, Eric WHALE
-
Publication number: 20160168274Abstract: The invention relates to plant-derived cellulose-containing particles useful as strengthening agents in water based systems and to a process for preparing cellulose-containing particles from plant material, which process involves treating said plant material with a peroxide reagent. The process can be controlled to produce cellulose-containing particle having a viscosity up to about 2500 cps.Type: ApplicationFiled: March 18, 2014Publication date: June 16, 2016Inventors: David HEPWORTH, Eric WHALE
-
Publication number: 20160168275Abstract: The present invention is directed to a process for producing spinnable cellulose at least in part from citrus fruits, such as oranges and lemons. In a preferred embodiment, cellulose is extracted from citrus fruits, discarded by the citrus fruits plantations and/or from parts of citrus fruits, waste of the industrial processing of citrus fruits derivatives. Cellulose is extracted from the entire peel of citrus fruits, which includes both albedo and flavedo, or only from albedo. Preferably, cellulose is obtained by chemical extraction, preferably in the absence of chlorine, comprising the treatment of raw materials derived from citrus fruits with hydrogen peroxide under basic conditions. Cellulose obtained by the process of the present invention is optionally mixed with cellulose obtained by different processes, for example with cellulose extracted from wood.Type: ApplicationFiled: July 30, 2014Publication date: June 16, 2016Inventor: Adriana Maria SANTANOCITO
-
Publication number: 20160168276Abstract: A process of making low-endotoxin chitosan or alkali-stable polysaccharide) The process may be generally performed by: suspending bulk chitosan fibers (or other suitable polysaccharide) having endotoxins therein to form a reaction mixture comprising an aqueous solution of alcohol; adding ammonia to the reaction mixture to raise pH of the reaction mixture to above 9.5; heating the reactive mixture with a pH above 9.5 at temperatures of at least 130 C for at least 20 minutes; cooling the reaction mixture to less than 60 C; sparging the cooled reaction mixture with an inert gas to remove ammonia; at least partially separating the chitosan fibers (or other suitable polysaccharide) from liquid carrier; rinsing the chitosan fibers (or other polysaccharide) with an endotoxin-free aqueous liquid to form a rinsed fiber mass; rinsing the rinsed fiber mass with an alcoholic liquid to remove water; and drying the fiber mass at a temperature below 100° C.Type: ApplicationFiled: December 16, 2014Publication date: June 16, 2016Inventors: James F. Drake, David R. Senogles
-
Publication number: 20160168277Abstract: The present invention relates to a process for producing a low endotoxin alkali chitosan, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan with an alkali solution to form a mixture and leaving the mixture for at least about 12 hours. The low endotoxin alkali chitosan may be used the manufacture of other useful chitosan based products.Type: ApplicationFiled: February 24, 2016Publication date: June 16, 2016Inventors: June Gladman, Craig Hardy, Andrew Hoggarth
-
Publication number: 20160168278Abstract: Provided is a method for operating a gas-phase, fluidized-bed reactor. The method has the steps of (a) receiving a signal from a probe in contact with the interior of the reactor or a process component in communication with the reactor, wherein the signal is derived from a physical property or condition within the reactor or the process component; (b) modifying the signal to create a modified signal; and (c) adjusting one or more operating parameters of the reactor in response to the modified signal if the physical property or condition is different than a desired value. There is also a method for reducing fouling in a distributor plate of a gas-phase, fluidized-bed reactor with a recycle line.Type: ApplicationFiled: December 3, 2015Publication date: June 16, 2016Applicant: ExxonMobil Research and Engineering CompanyInventors: Joseph Andres Moebus, William Anthony Lamberti, Harry William Deckman, Charles R. Buhler, Judson Sidney Clements
-
Publication number: 20160168279Abstract: Compounds of the formula I wherein m is 1 or 2; R1, R2, R4 and R5 independently of one another are hydrogen, C1-C4alkyl, C5-C7 cycloalkyl, phenyl, C1-C4alkoxy, C5-C7cycloalkoxy or phenoxy; R3, if m is 1, has one of the meanings as given above for R1, R2, R4 and R5; R3, if m is 2, is a divalent group; R6 is hydrogen or C1-C4alkyl; R7 is hydrogen, and if R6 is hydrogen then R7 may additionally be C1-C4alkyl; R8 is group A or B X is O, O—CH2— or —O(CHR14)—; n is 0-10; provided that (i) if n is 0, and X is O, then R8 is a group A; (ii) if n is other than 0, then X is O and R8 is the group A; R9 and R10 independently of one another are hydrogen or C1-C4alkyl; R11 and R12 independently of one another are C1-C4alkyl or form together with the C atom to which they are attached a 5 to 7 membered saturated carbocyclic ring; R13 is hydrogen, C1-C4alkyl, C5-C7cycloalkyl, 2-tetrahydropyranyl or Si(C1-C4alkyl)3; R14 is a group A? and R?13 has one of the meanings as given for R13 or is the group CType: ApplicationFiled: October 16, 2013Publication date: June 16, 2016Inventors: PETER NESVADBA, Jean-Luc BIRBAUM, Yvonne PILAK, Brun SPONY, Florian ZIEGLER
-
Publication number: 20160168280Abstract: A metallocene complex according to formula 1 wherein M is a metal selected from lanthanides or transition metals from group 3, 4, 5, or 6, Q is an anionic ligand to M, k is the number of Q groups and equals the valence of M minus 2, X is a cyclic bridging group that is bonded to a carbon atom of the cyclopentadienyl ligand and to nitrogen, Z1, and Z4 are hydrogen or a hydrocarbon radical with 1-20 carbon atoms; adjacent substituents Z2 and Z3 and are connected to form an indenyl or tetrahydroindenyl ring system and R is hydrogen or a hydrocarbon radical with 1-20 carbon atoms. Also described is a composition comprising the metallocene complex, a process for the preparation of the complex, and a process for the polymerization of olefin polymers in the presence of the metallocene complex.Type: ApplicationFiled: July 29, 2014Publication date: June 16, 2016Inventors: Nedumbamana SANKARAN, Prashant Sukumar SHINGE, Sharankumar SHETTY, Girish CHANDRA, Haif AL-SHAMMARI, Abdulaziz Hamad AL-HUMYDI, Edward Joseph NESAKUMAR
-
Publication number: 20160168281Abstract: The present invention relates to a novel metallocene compound, a catalyst composition including the same, and a method of preparing an olefinic polymer by using the same. The metallocene compound according to the present invention and the catalyst composition comprising the same can be used for producing olefinic polymers, have outstanding polymerizing ability, and can produce olefinic polymers of ultra high molecular weight. In particular, when the metallocene compound according to the present invention is employed, an olefinic polymer of ultra high molecular weight can be obtained because it shows high polymerization activity even when it is supported on a carrier and maintains high activity even in the presence of hydrogen because of its low hydrogen reactivity.Type: ApplicationFiled: October 11, 2013Publication date: June 16, 2016Inventors: Yong Ho LEE, Eun Kyoung SONG, Kyung Jin CHO, Ki Soo LEE, Se Young KIM, Sung Min LEE, Hyuck Ju KWON, Yi Young CHOI, Heon Yong KWON, Min Seok CHO, Dae Sik HONG
-
Publication number: 20160168282Abstract: A process for preparing isobutene homo- or copolymer derivatives by (i) polymerizing isobutene or an isobutene-comprising monomer mixture in the presence of an iron halide-donor complex, an aluminum trihalide-donor complex, or an alkylaluminum halide-donor complex, (ii) reacting a resulting high-reactivity isobutene polymer with a compound which introduces a low molecular weight polar group or a substructure thereof, and (iii) in the case of reaction with a substructure, further reacting to complete the formation of the low molecular weight polar group. The homo- or copolymer derivatives include a radical of a hydrophobic polyisobutene polymer having a number-average molecular weight of 110 to 250 000 and low molecular weight polar groups including amino functions, nitro groups, hydroxyl groups, mercaptan groups, carboxylic acid or carboxylic acid derivative functions, sulfonic acid or sulfonic acid derivative functions, aldehyde functions and/or silyl groups.Type: ApplicationFiled: February 18, 2016Publication date: June 16, 2016Applicant: BASF SEInventors: Hannah Maria KOENIG, Klaus MUEHLBACH, Helmut MACH, Ulrich EICHENAUER
-
Publication number: 20160168283Abstract: Molecular precursor chromium compounds and chromium on silica catalyst precursors suitable for sure in producing chromium on silica catalysts are disclosed. The molecular precursor compounds can be chromium(II) and/or chromium(III) and/or chromium (IV) compounds wherein all ligands are easily removable, in particular ligands selected from the group consisting of anionic ligands of the type —O—CR3R4—CH—R1—R2 or —O—Si—(O—CR3R4—CH—R1R2)3 wherein R1, R2, R3 and R4 may be the same or different and may be any group that does not affect decomposition of the ligand via elimination of beta-hydrogen from —CR3R4—CH—R1R2, amide anionic ligands of the type —N—Si—R5R6R7 and/or —N—C—R5R6R7, wherein R5, R6 and R7 can be the same or different and are preferably selected from hydrogen, methyl groups, ethyl groups, n-propyl groups, iso-propyl groups, tert-butyl groups or aromatic groups; as well as coordinating solvents.Type: ApplicationFiled: July 17, 2014Publication date: June 16, 2016Inventors: Christophe Copéret, Matthew Conley, Murielle Delley
-
Publication number: 20160168284Abstract: Methods for preparing metallocene-based catalyst systems containing an activator-support are disclosed. These methods can include contacting a solid metallocene compound, an activator-support, and an organoaluminum compound, resulting in catalyst systems with increased catalytic activity as compared to catalyst systems utilizing a solution of the metallocene compound.Type: ApplicationFiled: February 22, 2016Publication date: June 16, 2016Inventors: Kensha M. Clark, Qing Yang, Gary L. Glass
-
Publication number: 20160168285Abstract: A process for the preparation of a propylene homopolymer in a multistage polymerisation process in the presence of a single site catalyst, said process comprising: (I) in a slurry polymerisation step, polymerising propylene in the presence of said single site catalyst; and subsequently (II) in a gas polymerisation step polymerising propylene in the presence of catalyst and polymer from step (I) so as to form a propylene homopolymer; wherein said catalyst comprises (i) a metallocene complex of a Group 4 metal, said metallocene comprising at least two cyclopentadienyl type ligands; (ii) a boron based cocatalyst; and (iii) an aluminoxane cocatalyst; said catalyst being in solid form, preferably in solid particulate form, and being free from an external carrier.Type: ApplicationFiled: July 22, 2014Publication date: June 16, 2016Applicant: BOREALIS AGInventors: Luigi Resconi, Wilfried Töltsch, Noureddine Ajellal, Ville Virkkunen, Ismo Lehtiniemi
-
Publication number: 20160168286Abstract: A reaction resin composition having a resin component which contains a radically polymerizable compound and having an initiator system which comprises a copper(II) salt and at least one nitrogen-containing ligand, . . . and the copper(II) salt and the reducing agent being separated from each other in a reaction-inhibiting manner, and the use thereof for construction purposes are described.Type: ApplicationFiled: July 9, 2014Publication date: June 16, 2016Inventor: Armin PFEIL